Neurofilament light chain in serum of cancer patients with acute neurological complications

Aim: Neurofilament light chain (NfL) is a nonspecific sensitive biomarker of axonal damage.Methods: This case series identified cancer patients with neurological complications who had serum NfL measurements and paired these results to outcomes.Results: NfL serum levels were available in 15 patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Amulya Gottiparthy, Keng Lam, Suprateek Kundu, Zixi Yang, Ivo Tremont-Lukats, Sudhakar Tummala
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:CNS Oncology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/20450907.2024.2386233
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850220215899521024
author Amulya Gottiparthy
Keng Lam
Suprateek Kundu
Zixi Yang
Ivo Tremont-Lukats
Sudhakar Tummala
author_facet Amulya Gottiparthy
Keng Lam
Suprateek Kundu
Zixi Yang
Ivo Tremont-Lukats
Sudhakar Tummala
author_sort Amulya Gottiparthy
collection DOAJ
description Aim: Neurofilament light chain (NfL) is a nonspecific sensitive biomarker of axonal damage.Methods: This case series identified cancer patients with neurological complications who had serum NfL measurements and paired these results to outcomes.Results: NfL serum levels were available in 15 patients with hematological malignancies or solid tumors. The neurological complications studied were immune effector cell–associated neurotoxicity syndrome, immune checkpoint inhibitor–related encephalopathy, anoxic brain injury, Guillain-Barre syndrome, hemophagocytic lymphohistiocytosis, transverse myelitis, paraneoplastic syndrome, central nervous system demyelinating disorder and chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. All patients but one with serum NfL >900 pg/ml died during hospitalization.Conclusion: Serum NfL levels consistently corresponded to death, disease severity or recovery in this series.
format Article
id doaj-art-3e438a3cd4284e5cafa6ba00ee389bb6
institution OA Journals
issn 2045-0907
2045-0915
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series CNS Oncology
spelling doaj-art-3e438a3cd4284e5cafa6ba00ee389bb62025-08-20T02:07:09ZengTaylor & Francis GroupCNS Oncology2045-09072045-09152024-12-0113110.1080/20450907.2024.2386233Neurofilament light chain in serum of cancer patients with acute neurological complicationsAmulya Gottiparthy0Keng Lam1Suprateek Kundu2Zixi Yang3Ivo Tremont-Lukats4Sudhakar Tummala5Stanley H. Appel Department of Neurology, Houston Methodist Hospital, Houston, TX 77030, USADepartment of Neuro-Oncology, Division of Cancer Medicine, Unit 431, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Biostatistics, Unit 1411, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Biostatistics, Unit 1411, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAKenneth R Peak Brain & Pituitary Tumor Center, Houston Methodist Hospital, Houston, TX 77030, USADepartment of Neuro-Oncology, Division of Cancer Medicine, Unit 431, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAAim: Neurofilament light chain (NfL) is a nonspecific sensitive biomarker of axonal damage.Methods: This case series identified cancer patients with neurological complications who had serum NfL measurements and paired these results to outcomes.Results: NfL serum levels were available in 15 patients with hematological malignancies or solid tumors. The neurological complications studied were immune effector cell–associated neurotoxicity syndrome, immune checkpoint inhibitor–related encephalopathy, anoxic brain injury, Guillain-Barre syndrome, hemophagocytic lymphohistiocytosis, transverse myelitis, paraneoplastic syndrome, central nervous system demyelinating disorder and chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. All patients but one with serum NfL >900 pg/ml died during hospitalization.Conclusion: Serum NfL levels consistently corresponded to death, disease severity or recovery in this series.https://www.tandfonline.com/doi/10.1080/20450907.2024.2386233cancercentral nervous systemNeurofilament light chainneurotoxicityperipheral nervous system
spellingShingle Amulya Gottiparthy
Keng Lam
Suprateek Kundu
Zixi Yang
Ivo Tremont-Lukats
Sudhakar Tummala
Neurofilament light chain in serum of cancer patients with acute neurological complications
CNS Oncology
cancer
central nervous system
Neurofilament light chain
neurotoxicity
peripheral nervous system
title Neurofilament light chain in serum of cancer patients with acute neurological complications
title_full Neurofilament light chain in serum of cancer patients with acute neurological complications
title_fullStr Neurofilament light chain in serum of cancer patients with acute neurological complications
title_full_unstemmed Neurofilament light chain in serum of cancer patients with acute neurological complications
title_short Neurofilament light chain in serum of cancer patients with acute neurological complications
title_sort neurofilament light chain in serum of cancer patients with acute neurological complications
topic cancer
central nervous system
Neurofilament light chain
neurotoxicity
peripheral nervous system
url https://www.tandfonline.com/doi/10.1080/20450907.2024.2386233
work_keys_str_mv AT amulyagottiparthy neurofilamentlightchaininserumofcancerpatientswithacuteneurologicalcomplications
AT kenglam neurofilamentlightchaininserumofcancerpatientswithacuteneurologicalcomplications
AT suprateekkundu neurofilamentlightchaininserumofcancerpatientswithacuteneurologicalcomplications
AT zixiyang neurofilamentlightchaininserumofcancerpatientswithacuteneurologicalcomplications
AT ivotremontlukats neurofilamentlightchaininserumofcancerpatientswithacuteneurologicalcomplications
AT sudhakartummala neurofilamentlightchaininserumofcancerpatientswithacuteneurologicalcomplications